Business
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26
[ad_1]
Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26.
Key Financial Highlights
Q2 FY26 Standalone Financial Highlights
• Total Income of ₹ 145.29 Cr, YoY growth of 35.34%
• EBITDA of ₹ 22.34 Cr, YoY growth of 60.09%
• EBITDA…
[ad_2]
Source link
Continue Reading